Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus
Laura Lazoa b c d✉, Alienys Izquierdoe, Edith Suzartea, Lázaro Gila, Iris Valdésa, Ernesto Marcosa, Mayling Álvareze, Yaremis Romeroa, María Guadalupe Guzmáne, Gerardo E Guilléna, Lisset Hermidaa
- aVaccines Division Center for Genetic Engineering and Biotechnology P.O. Box 6162 Playa Havana 11 600 Cuba
- bVaccines Division
- cCenter for Genetic Engineering and Biotechnology
- dP.O. Box 6162 Playa Havana 11 600 Cuba
- eVirology Department Tropical Medicine Institute “Pedro Kourí,” Pan American Health Organization/World Health Organization Collaborating Center for the Study of Dengue and its Vector P.O. Box Marianao 13 Havana 11 600 Cuba
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
A dengue vaccine must induce protective immunity against the four serotypes of the virus. Our group has developed chimeric proteins consisting of the protein P64k from Neisseria meningitidis and the domain III from the four viral envelope proteins. In this study, the immunogenicity of a tetravalent vaccine formulation using aluminum hydroxide as adjuvant was evaluated in mice. After three doses, neutralizing antibody titers were detected against the four viral serotypes, the lowest seroconversion rate being against dengue virus serotype 4. One month after the last dose, immunized animals were challenged with infective virus, and partial but statistically significant protection was found to have been achieved. Based on these results, further studies in mice and non-human primates using this tetravalent formulation in a prime-boost strategy with attenuated viruses are strongly recommended.
TL;DRIn this study, the immunogenicity of a tetravalent vaccine formulation using aluminum hydroxide as adjuvant was evaluated in mice and partial but statistically significant protection was found to have been achieved. (Semantic Scholar)